Leerink Partners maintains Veradermics at Outperform, raises price target to $150 from $135
Leerink Partners kept Veradermics at Outperform, raising its price target to $150 from $135, an 11.1% increase. This implies a 4.2% upside from the Nov 9 close of $143.95. Recent analyst targets range from $172 to $204.
How this was made

The 30-second read
Why it matters
Limited impact as the change is small and lacks supporting news.
Market read
Minor analyst rating change with minimal trading relevance.
What to watch
No new fundamental data accompanies the rating change.
Background
Analyst rating update for Veradermics with a modest price target increase.
Market effects
none
none
none
Counterpoint
The target raise is modest and may already be priced in.
Key entities
- CompanyVeradermics
Subject of the analyst rating update.